靶向抑制PD-L1/PD-1的免疫治疗恶性黑色素瘤新进展  

Advance Development of Immunotherapy on Malignant Melanoma with Targeting Inhibition of PD-L1/PD-1

作　　者：鹿玉印 郭秀丽[1] 

机构地区：[1]山东大学药学院新药药理研究所,济南250012

出　　处：《中国药学杂志》2015年第22期1931-1935,共5页Chinese Pharmaceutical Journal

基　　金：国家自然科学基金资助项目(81373450)

摘　　要：恶性黑色素瘤具有转移早、进展快、预后差、死亡率高等特点,对于临床医生来说是一个非常大的挑战。当前治疗转移性黑色素瘤的医学手段也因这些特点应用有限。近年来随着免疫治疗晚期黑色素瘤机制的深入研究,一大批治疗恶性黑色素瘤的抗体药物进入临床研究阶段。特别是2014年新型免疫药物抗程序性死亡配体(PD-L1)/程序性死亡受体-1抗体药物pembrolizumab和nivolumab顺利通过Ⅲ期临床试验先后被FDA批准上市,为那些不可切除的或转移的晚期黑色素瘤患者带来了生存的希望。笔者就抗程序性死亡配体-1/程序性死亡受体-1抗体药物治疗黑色素的现状及进展作一综述,为黑色素瘤的新药开发和临床治疗提供参考。Malignant melanoma presents a significant therapeutic challenge to clinicians with characteristics of early metastasis,rapid development,poor prognosis and high mortality. Many therapies for metastatic melanoma are limited by these characteristics.With the development of immunotherapy mechanism for malignant melanoma,a large number of antibody agents for the treatment of malignant melanoma entered the clinical trials. To our great delight,the new drugs of pembrolizumab and nivolumab have been approved by FDA in 2014 after successfully passing phase Ⅲ clinical trial,which bring a chance of survival to patients with unresectable or metastatic advance melanoma. This review briefly discusses recent development and advances of anti-PD-L1 / PD-1 antibody drugs against melanoma.

关 键 词：黑色素瘤 免疫治疗 抗程序性死亡受体-1抗体药物 抗程序性死亡配体-1抗体药物 

分 类 号：R965[医药卫生—药理学]